Why the study?
Does oral disopyramide phosphate prevent the laboratory induction of paroxysmal supraventricular tachycardia in patients with clinical PSVT?
Population
16 patients with clinical paroxysmal supraventricular tachycardia and inducible, sustained PSVT during a…
Comparison
Oral disopyramide phosphate 200-300 mg for three… vs Baseline
Design
Cohort
Follow-up
24 hours
Authors
Loading...
Supports disopyramide for select refractory PSVT; leaves open whether inducibility changes predict clinical outcomes.
Does oral disopyramide phosphate prevent the laboratory induction of paroxysmal supraventricular tachycardia in patients with clinical PSVT?
Oral disopyramide phosphate prevents the laboratory induction of PSVT in 50% of patients, suggesting it may be effective in preventing clinical recurrences in selected individuals.
Swiryn et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: